On November 7, 2019 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, reported that they have entered a preclinical research collaboration to explore the potential combinatory effect of their platform-based immunotherapies (Press release, Navidea Biopharmaceuticals, NOV 7, 2019, View Source [SID1234550666]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The purpose of this collaboration is to conduct preclinical studies to evaluate the combinatory effect of Navidea’s proprietary activated macrophage targeting therapeutics along with IMV’s DPX-based immunotherapies. Navidea and IMV will jointly conduct the research throughout the duration of the study.
"We are thrilled to begin this collaboration with IMV to investigate the use of their DPX platform technology in conjunction with Navidea’s in a relevant preclinical tumor model," said Michael Rosol, PhD, Chief Medical Officer at Navidea Biopharmaceuticals. "The combination of IMV’s DPX-based immunotherapies with Navidea’s CD206-targeted therapeutic could lead to a powerful new approach to treating a variety of cancers."
Marianne Stanford, PhD, Vice President Research & Development at IMV Inc., said, "At IMV, we continue to explore new combinations for our DPX-based compounds and seek all possible ways to tackle hard-to-treat cancers. We are pleased to collaborate with Navidea Biopharmaceuticals and hope to identify novel targets for further clinical studies."